Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results.
紐約州斯托尼布魯克 / ACCESSWIRE / 2025年1月8日 / Applied DNA Sciences, Inc. (納斯達克:APDN)（「Applied DNA」或「公司」），作爲一家聚合酶鏈反應（PCR）技術的領先公司，今天宣佈已將其投資者更新電話會議重新安排至2025年2月13日（星期四），以與其2025財年第一季度財務報告的發佈相一致。
The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative. The change reflects the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.
公司最初計劃在2025年1月9日召開投資者更新電話會議，以更新股東有關2024年12月宣佈的戰略重組和GMP計劃的情況。此更改反映了全國哀悼日的遵守，以紀念前總統吉米·卡特的逝世。
About Applied DNA Sciences
關於Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Applied DNA Sciences是一家生物技術公司，致力於開發用於生產和檢測脫氧核糖核酸（「DNA」）的技術。我們使用聚合酶鏈反應（「PCR」）來實現DNA的生產和檢測，目前我們在三個主要業務市場運營： (i) 酶促合成DNA的製造，用於生產核酸類治療藥物以及開發和銷售專有RNA聚合酶（「RNAP」），用於生產mRNA治療藥物； (ii) 在分子診斷和基因檢測服務中檢測DNA和RNA；及 (iii) 爲工業供應鏈安防服務製造和檢測DNA。
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
訪問adnas.com以獲取更多信息。請在X和LinkedIn上關注我們。加入我們的郵件列表。
For additional information:
更多信息：
Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
投資者關係：Sanjay m. Hurry，917-733-5573，sanjay.hurry@adnas.com
Web:
網站:
SOURCE: Applied DNA Sciences, Inc.
來源：Applied DNA Sciences, Inc.
譯文內容由第三人軟體翻譯。
